HI
SUPN icon

Horizon Investments’s Supernus Pharmaceuticals SUPN Stock Holding History

Horizon Investments’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$655K Sell
12,677
-600
-5% -$30.6K 0.01% 829
2025
Q4 		$660K Sell
13,277
-9,928
-43% -$483K 0.01% 748
2025
Q3 		$1.11M Buy
23,205
+9,202
+66% +$371K 0.01% 604
2025
Q2 		$441K Buy
+14,003
New +$449K 0.01% 826

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Horizon Investments's SUPN Position: Q1 2026 in Review

Horizon Investments reduced its Supernus Pharmaceuticals (SUPN) stake by 4.5% in Q1 2026, selling an estimated $30.6K and leaving 12,677 shares worth $655K. The position accounts for 0.01% of the portfolio, ranked #829.

Horizon Investments first reported a position in SUPN in Q2 2025 and has held it in 4 quarters since. The position peaked at $1.11M in Q3 2025. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Horizon Investments held 12,677 shares of Supernus Pharmaceuticals worth $655K as of Q1 2026.
  • Horizon Investments sold 600 Supernus Pharmaceuticals shares in Q1 2026, an estimated $30.6K.
  • Supernus Pharmaceuticals made up 0.01% of Horizon Investments's portfolio in Q1 2026, its #829 holding.
  • Horizon Investments first reported a position in Supernus Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • Horizon Investments's Supernus Pharmaceuticals position peaked at $1.11M in Q3 2025.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Horizon Investments's 13F filing for Q1 2026, filed 15 May 2026.